Abstract 18P
Background
Vitamin C (VitC) was shown to synergize with immune checkpoint blockade in tumor bearing immunocompetent mice, which provided the rationale for the ongoing ALFEO trial in colorectal cancer patients (Clinical Trial Registration Number 2022-502101-15-00). In this work, we aimed to elucidate the molecular mechanisms underlying these preclinical observations. We hypothesized that VitC could strain cancer cells, which react by emitting danger signal molecules, which in turn could stimulate an immune mediated anticancer response.
Methods
We assessed expression of the oxidative stress marker hydroxyguanosine (8-OHG) and danger signal molecules (calreticulin and HMGB1) in breast and colon murine tumors treated with VitC. A calreticulin blocking antibody was given in combination with VitC to functionally ascertain the role of this stress signal protein.
Results
Pharmacological doses of VitC were able to strongly induce oxidative stress as indicated by strong 8-OHG staining in tumor sections. VitC-stressed tumor cells mobilized the danger molecules calreticulin and HMGB1. Although the induction of these danger markers was seen in tumors grown both in immunocompromised and immunocompetent VitC treated mice, its anticancer activity was evident only in the presence of an intact immune system. In vivo, a calreticulin blocking antibody effectively prevented its translocation and inhibited HMGB1 release in murine tumors. Notably, preventing calreticulin exposure abrogated the immunomediated anticancer effect of VitC. VitC enhanced the infiltration of natural killers, activated CD8+ T lymphocytes, while it decreased the number of Tregs. Calreticulin blockade impaired the modulation of the immune tumor microenvironment induced by VitC.
Conclusions
We unveil that VitC is able to mobilize calreticulin and HMGB1, which are among the established markers of immunogenic cell death. These results, alongside the observation that VitC exerts its maximal antitumor activity only in immunocompetent mice are clues that VitC could act as immunogenic cell death inducer when given at pharmacological doses. Our findings have implications for cancer patients enrolled in clinical trials based on VitC containing regimens
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIRC.
Disclosure
P.P. Vitiello: Financial Interests, Personal, Speaker, Consultant, Advisor: Biocartis, Merck. G. Germano: Other, Personal, Advisory Board: NeoPhore. A. Bardelli: Financial Interests, Personal, Advisory Role: Illumina, Inivata; Financial Interests, Personal, Advisory Board: NeoPhore. F. Di Nicolantonio: Financial Interests, Personal, Speaker, Consultant, Advisor: Illumina, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09